656 related articles for article (PubMed ID: 17672075)
21. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
22. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.
Redman AR; Zheng J; Shamsi SA; Huo J; Kelly EJ; Ho RJ; Ritchie DM; Hon YY
Clin Appl Thromb Hemost; 2008 Jan; 14(1):29-37. PubMed ID: 17895500
[TBL] [Abstract][Full Text] [Related]
23. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
24. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
Caraco Y; Blotnick S; Muszkat M
Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
[TBL] [Abstract][Full Text] [Related]
25. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
[TBL] [Abstract][Full Text] [Related]
26. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
[TBL] [Abstract][Full Text] [Related]
27. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
[TBL] [Abstract][Full Text] [Related]
28. [Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Khasanova ZB; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(12):43-8. PubMed ID: 22416444
[TBL] [Abstract][Full Text] [Related]
29. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial.
Colli A; Mestres CA; Castella M; Gherli T
J Heart Valve Dis; 2007 Nov; 16(6):667-71. PubMed ID: 18095518
[TBL] [Abstract][Full Text] [Related]
30. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
31. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Ruud E; Holmstrøm H; Bergan S; Wesenberg F
Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
[TBL] [Abstract][Full Text] [Related]
32. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
Samardzija M; Topić E; Stefanović M; Zibar L; Samardzija G; Balen S; Vcev A; Domanović D; Mirat J; Barbić J
Coll Antropol; 2008 Jun; 32(2):557-64. PubMed ID: 18756910
[TBL] [Abstract][Full Text] [Related]
33. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.
Girón-González JA; García del Río E; Rodríguez C; Rodríguez-Martorell J; Serrano A
J Rheumatol; 2004 Aug; 31(8):1560-7. PubMed ID: 15290736
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
35. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
36. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
Levy Y; Shenkman B; Tamarin I; Pauzner R; Shoenfeld Y; Langevitz P; Savion N; Varon D
Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
[TBL] [Abstract][Full Text] [Related]
37. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
Ames PR; Margaglione M; Ciampa A; Colaizzo D; Ferrara F; Iannaccone L; Vincenzobrancaccio
Thromb Res; 2011 Jun; 127(6):595-9. PubMed ID: 21371740
[TBL] [Abstract][Full Text] [Related]
38. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
40. Current management of antiphospholipid syndrome-related thrombosis.
Puente D; Pombo G; Forastiero R
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1551-8. PubMed ID: 19954317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
